Types of COVID-19 Vaccines in Malaysia in Malaysia

As the world starts gearing up to combat the damaging COVID-19 pandemic with the release of vaccines, Malaysia has also jumped onto the bandwagon with reports of when and what vaccines the government has purchased for its 32 million people.

Affirmative plans involved

Vaccines for COVID-19 will come from several sources most notably, the early adopters who claimed to have the highest efficacy. Malaysia was among the first Southeast Asia nation to have confirmed the purchase of COVID-19 vaccines and is expected to receive the first batch in February 2020. The distribution of the vaccines will be done in stages, much like how other countries are doing. Once all the vaccines are delivered, it should cover 70% of the entire population which are all adults. The remaining 30% are children which will not be given the vaccine first as the clinical trials were only conducted on adults.

Pfizer-BioNTech vaccine – February 2021

The first option is the Pfizer-BioNTech mRNA vaccine. This has been confirmed with the purchase of 12.8 million doses with the first batch expected in February 2021. This should cover 6.4 million of the total population of Malaysia as each person is required to take 2 doses each. The main issue with this vaccine is the logistics of distribution as it needs to be stored below refrigeration temperatures before it can be administered.

AstroZeneca Vaccine – Q2 2021

Following the Pfizer-BioNTech deal, the Malaysian government has further confirmed the purchase of the COVID-19 mRNA vaccine from the Oxford University-AstraZeneca. This agreement will cover 6.4 million doses of the vaccine which is expected to arrive in the second quarter of 2021 (April or May). That will be sufficient to cover an additional 3.2 million population (2 doses each). After that, there will be another 6.4 million expected around the same quarter through the Oxford University/AstraZeneca initiative from the COVAX project under WHO. With that, the COVID-19 vaccine will cover 40% of the total population of Malaysia.

Vaccines for the remaining population – Q2 2021 and after

With the confirmed purchase of vaccines from Pfizer-BioNTech and AstraZeneca, the Malaysian government is negotiating with 3 other manufacturers to cover the remaining population of the country. This includes:

  • Sinovac – This is a Chinese pharmaceutical company that is developing the CoronaVac. If confirmed, Malaysia would be expected to purchase 14 million of this vaccine which must be administered twice per person, covering 7 million people.
  • CanSino Biologics Inc – Another Chinese manufacturer, the government is negotiating to purchase 3.5 million of this vaccine which will cover 10.9% (3.5 million people) of the population.
  • Gamaleya – The Russian company manufactures the Gam-COVID-Vac and Malaysia is looking to purchase 6.4 million doses of this vaccine to cover 3.2 million people.

What is the outlook like?

If all the vaccines mentioned are confirmed and purchased, it would cover up to 82.8% of the Malaysian population. At the time of writing, there will be enough vaccines to cover 40% of the population or 12.8 million people and this is expected to increase in due time.